Share Name Share Symbol Market Type Share ISIN Share Description
Plant Health Care LSE:PHC London Ordinary Share GB00B01JC540 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 27.25p 27.00p 28.00p - - - 0 08:37:22
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 5.1 -9.2 -8.9 - 40.28

Plant Health Care PLC Research Update

18/01/2017 7:02am

UK Regulatory (RNS & others)

Plant Health Care (LSE:PHC)
Historical Stock Chart

1 Year : From Jul 2016 to Jul 2017

Click Here for more Plant Health Care Charts.


RNS Number : 4128U

Plant Health Care PLC

18 January 2017


("Plant Health Care", "PHC" or the "Company")

Plant Health Care(R) (AIM: PHC), a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to provide the following update in relation to its New Technology business.


 ð   Field trials with Innatus(TM) 3G in 2016 continued 
           to show good results, both in Plant Health Care's own 
           trials and those run by partners. All four evaluation 
           partners have now extended the terms of their contracts 
           into 2018. We are on track for the first competitive 
           licensing process to conclude in early 2018. 
 ð   Two new PREtec peptide platforms: T-Rex 3G and Y-Max 
           3G have been presented to industry players. First agreements 
           have been signed and more are expected over the coming 
           months. Field trials have begun and we are targeting 
           a revenue-generating licence before the end of 2017. 
 ð   Plant Health Care continues to make strong progress 
           in building its capability to make, to formulate and 
           to register PREtec peptides. This will accelerate first 
           sales, following the agreement of licences with partners. 

Innatus 3G

In 2016 Plant Health Care completed its fourth year of Innatus 3G field trials. Performance was in line with previous years. Results confirm the value of peptides from Innatus 3G for three critical agricultural uses - yield promotion, disease protection and drought resistance - all of which are very important commercial targets.

Peptides from the Innatus 3G platform were added to standard industry mixtures of agrochemicals and biologicals, and applied to seeds in the conventional way. Even in a year with close to ideal growing conditions, Innatus 3G provided substantial increases in harvest yield. This all supports our view that Innatus 3G will add significant value on top of conventional seed treatment applications.

PHC has four evaluation partners for Innatus 3G. Some of them conducted field trials on a larger scale than Plant Health Care has ever done. The larger the scale of their field trials, the more enthusiastic the partners were about their results. All four partners have extended the terms of their evaluation agreements into 2018.

Greenhouse studies commissioned by PHC during 2016 showed Innatus 3G peptides providing impressive resistance against certain fungal diseases. For example, young corn plants grown from treated seed that had been planted into soil infected with the Fusarium fungus displayed fewer symptoms of stem and root. This level of control matched or even exceeded control achieved by standard fungicide seed treatments. These results have been confirmed on a larger scale in partner trials, to statistically significant levels. This confirmed that Innatus 3G can protect crop yield against the pressure of various diseases under field conditions.

A field trial run by PHC in California gave strong indications that certain Innatus 3G peptides can substantially protect corn yield from the effects of drought. This confirmed the predictions of many small-scale tests run in Seattle.

T-Rex 3G and Y-Max 3G

Two new PREtec peptide platforms were presented to selected industry partners in 2016, supported by data from greenhouse and laboratory tests and limited field trials. Our target had been to present one platform but additional studies and encouragement from our partners persuaded us to move forward with two, so we are now ahead of plan.

      ð              T-Rex 3G is a platform that has been optimised for nematode 
                           suppression, which is a substantial market opportunity, 
                           with relatively few good commercial products today. Peptides 
                           from T-Rex 3G have been shown to give results comparable 
                           with or in some cases markedly superior to control achieved 
                           by chemical and biological commercial standards. Trials 
                           during 2016 showed peptides from T-Rex 3G protecting 
                           plants and suppressing the soil-borne populations of 
                           pest nematodes. 
      ð              Y-Max 3G behaves more like a classic biostimulant but 
                           has its own mode of action. When applied to corn and 
                           soy as a seed treatment it increases biomass and yield. 
                           2016 trials in corn showed that root structures were 
                           developed early and nutrient uptake was improved. Field 
                           trials have confirmed that seed treatment with Y-Max 
                           3G leads to increased corn yields. Biostimulants as a 
                           class have particular advantages in terms of the cost 
                           and speed of commercial registration. 
      ð              Responses to T-Rex 3G and Y-Max 3G have been very positive. 
                           The first agreements (with both new and existing partners) 
                           have already been signed, to explore these new platforms 
                           and field trials have begun. More evaluation agreements 
                           are expected to be signed over the coming months. PHC 
                           is aiming to secure its first revenue generating licence 
                           of one of these technologies in 2017. 

PHC's product development capability

As industry partners gain more confidence in the field performance of the technology, they are starting to pay detailed attention to other parameters, including the physical stability of peptides in formulations, and their compatibility with proprietary chemistry. Positive results in these areas are required before our partners take final development decisions.

With our expanded R&D facilities in Seattle operating well, PHC is well placed to support partners as they progress towards product development. We have run extensive compatibility and stability studies. We have also carried out initial fermentation production trials, utilising our extensive experience of this approach to produce our existing products. Early indications are very promising and we can now move much faster to optimise peptides for best performance in our partners' end products and early market entry.

 Plant Health Care plc 
 Dr Chris Richards, Executive Chairman      Tel: +44 (0) 18 3788 
  and Interim CEO                                           0083 
 Liberum Capital - Nomad and Broker 
 Clayton Bush / Chris Clarke                Tel: +44 (0) 20 3100 
 Company website: 

This information is provided by RNS

The company news service from the London Stock Exchange



(END) Dow Jones Newswires

January 18, 2017 02:02 ET (07:02 GMT)

1 Year Plant Health Care Chart

1 Year Plant Health Care Chart

1 Month Plant Health Care Chart

1 Month Plant Health Care Chart
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V:gb D:20170720 14:32:07